DURHAM: Chimerix announces new CEO after Moch resigns - WNCN: News, Weather

Chimerix announces new CEO after Moch resigns

Posted: Updated:
DURHAM, N.C. - Chimerix, the company that provided a lifesaving anti-viral drug to a sick boy in Virginia, has a new president and chief executive officer, the company announced Wednesday.

Chimerix has appointed Dr. M. Michelle Berrey as its new president and CEO. Berry replaces Kenneth I. Moch following his resignation.

In a release, Chimerix said Moch resigned from the role in order to “pursue other interests.”

Chimerix, which is based in Research Triangle Park, gained attention with its experimental anti-viral drug that could help save 7-year-old Josh Hardy’s life. Hardy’s heart and kidneys were failing due to an adenovirus infection.

Chimerix’s drug was not yet approved by the Food and Drug Administration because it was in the final stages of clinical trials. But the company and agency were able to reach an agreement to provide Hardy with the drug after an extensive public campaign waged by Josh's family.

"There is no doubt that the social media aspects of this helped to accelerate what had been an on-going dialog with the FDA," Moch said in a March interview.

Before becoming Chimerix’s new CEO, Berrey joined the company in 2012 as the company’s chief medical officer.

Copyright 2014 WNCN. All rights reserved.

Powered by WorldNow

1205 Front St., Raleigh
N.C., 27609

Telephone: 919.836.1717
Fax: 919.836.1687
Email: newstips@wncn.com

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Media General Communications Holdings, LLC. A Media General Company.